Hangzhou Alltest Biotech Co. Ltd. A (688606) - Total Assets
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) holds total assets worth CN¥4.11 Billion CNY (≈ $601.28 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688606 stock price and chart for real-time trading data and today's change.
Hangzhou Alltest Biotech Co. Ltd. A - Total Assets Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see Hangzhou Alltest Biotech Co. Ltd. A cash conversion from operations for how efficiently the company converts equity into cash flow.
Hangzhou Alltest Biotech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou Alltest Biotech Co. Ltd. A's total assets of CN¥4.11 Billion consist of 66.8% current assets and 33.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.2% |
| Accounts Receivable | CN¥159.05 Million | 3.8% |
| Inventory | CN¥176.69 Million | 4.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥136.82 Million | 3.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688606 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Alltest Biotech Co. Ltd. A's current assets represent 66.8% of total assets in 2025, a decrease from 92.0% in 2016.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2025, up from 13.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 4.2% of total assets.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Total Assets
Key competitors of Hangzhou Alltest Biotech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
China | CN¥1.64 Billion |
|
Medeon Biodesign
TWO:6499
|
Taiwan | NT$1.68 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Hangzhou Alltest Biotech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.36 | 11.70 | 16.58 |
| Quick Ratio | 11.51 | 11.06 | 15.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.47 Billion | CN¥2.72 Billion | CN¥2.67 Billion |
Hangzhou Alltest Biotech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Hangzhou Alltest Biotech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥4.24 Billion |
| Market Capitalization | $556.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Alltest Biotech Co. Ltd. A's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hangzhou Alltest Biotech Co. Ltd. A's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
The table below shows the annual total assets of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.24 Billion ≈ $620.80 Million |
+1.35% |
| 2024-12-31 | CN¥4.19 Billion ≈ $612.55 Million |
+1.70% |
| 2023-12-31 | CN¥4.12 Billion ≈ $602.31 Million |
-12.42% |
| 2022-12-31 | CN¥4.70 Billion ≈ $687.72 Million |
+17.25% |
| 2021-12-31 | CN¥4.01 Billion ≈ $586.55 Million |
+248.22% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.44 Million |
+246.19% |
| 2019-12-31 | CN¥332.50 Million ≈ $48.66 Million |
+30.62% |
| 2018-12-31 | CN¥254.56 Million ≈ $37.25 Million |
+33.57% |
| 2017-12-31 | CN¥190.58 Million ≈ $27.89 Million |
+219.06% |
| 2016-12-31 | CN¥59.73 Million ≈ $8.74 Million |
-- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more